NasdaqGS:EPZM

Stock Analysis Report

Executive Summary

Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States.


Snowflake Analysis

Excellent balance sheet with limited growth.

Share Price & News

How has Epizyme's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: EPZM's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0.06%

EPZM

0.3%

US Biotechs

-2.6%

US Market


1 Year Return

13.4%

EPZM

1.9%

US Biotechs

-13.3%

US Market

Return vs Industry: EPZM exceeded the US Biotechs industry which returned 1.9% over the past year.

Return vs Market: EPZM exceeded the US Market which returned -13.3% over the past year.


Shareholder returns

EPZMIndustryMarket
7 Day0.06%0.3%-2.6%
30 Day-29.5%-5.6%-15.2%
90 Day-36.4%-3.9%-22.2%
1 Year13.4%13.4%2.7%1.9%-11.5%-13.3%
3 Year5.0%5.0%17.2%14.3%13.2%5.7%
5 Year-20.6%-20.6%-5.7%-10.1%31.8%17.2%

Price Volatility Vs. Market

How volatile is Epizyme's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Epizyme undervalued compared to its fair value and its price relative to the market?

5.09x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate EPZM's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate EPZM's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: EPZM is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: EPZM is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate EPZM's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: EPZM is overvalued based on its PB Ratio (5.1x) compared to the US Biotechs industry average (2.5x).


Next Steps

Future Growth

How is Epizyme forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

48.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: EPZM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: EPZM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: EPZM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: EPZM's revenue (47.4% per year) is forecast to grow faster than the US market (7% per year).

High Growth Revenue: EPZM's revenue (47.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: EPZM is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Epizyme performed over the past 5 years?

-8.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EPZM is currently unprofitable.

Growing Profit Margin: EPZM is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: EPZM is unprofitable, and losses have increased over the past 5 years at a rate of -8.9% per year.

Accelerating Growth: Unable to compare EPZM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EPZM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).


Return on Equity

High ROE: EPZM has a negative Return on Equity (-51.43%), as it is currently unprofitable.


Next Steps

Financial Health

How is Epizyme's financial position?


Financial Position Analysis

Short Term Liabilities: EPZM's short term assets ($399.2M) exceed its short term liabilities ($34.4M).

Long Term Liabilities: EPZM's short term assets ($399.2M) exceed its long term liabilities ($59.1M).


Debt to Equity History and Analysis

Debt Level: EPZM's debt to equity ratio (10.9%) is considered satisfactory.

Reducing Debt: EPZM's debt to equity ratio has increased from 0.01% to 10.9% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: EPZM has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: EPZM has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of -16.4% each year.


Next Steps

Dividend

What is Epizyme's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate EPZM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate EPZM's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EPZM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EPZM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EPZM's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Bob Bazemore (51yo)

4.58s

Tenure

US$3,650,871

Compensation

Mr. Robert B. Bazemore, also known as Bob, has been the Chief Executive Officer and President at Epizyme, Inc. since September 10, 2015 and serves as its Secretary. He has been a Director of Ardelyx, Inc.  ...


CEO Compensation Analysis

Compensation vs Market: Bob's total compensation ($USD3.65M) is about average for companies of similar size in the US market ($USD4.74M).

Compensation vs Earnings: Bob's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Robert Bazemore
President4.58yrsUS$3.65mno data
Matthew Ros
Chief Strategy & Business Officer0.67yrUS$1.72m0.015% $235.9k
Shefali Agarwal
Chief Medical Officer1.83yrsUS$2.00m0.012% $181.7k
H. Horvitz
Co-Founder & Chairman of the Scientific Advisory Boardno datano datano data
Yi Zhang
Scientific Co-Founder & Member of The Scientific Advisory Boardno datano datano data
Paolo Tombesi
Chief Financial Officer0.67yrno data0.0037% $57.3k
Joseph Beaulieu
Controller1.25yrsno data0.0024% $36.5k
Jeffery Kutok
Chief Scientific Officer0.083yrno datano data
Jason Fredette
Vice President of Investor Relationsno datano datano data
John Weidenbruch
General Counselno datano datano data

1.0yrs

Average Tenure

52yo

Average Age

Experienced Management: EPZM's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Robert Bazemore
President4.58yrsUS$3.65mno data
H. Horvitz
Co-Founder & Chairman of the Scientific Advisory Boardno datano datano data
Yi Zhang
Scientific Co-Founder & Member of The Scientific Advisory Boardno datano datano data
George Daley
Member of the Scientific Advisory Boardno datano datano data
David Mott
Independent Chairman4yrsUS$242.08k0.059% $914.9k
Carl Goldfischer
Independent Director10.58yrsUS$198.92kno data
Christopher Walsh
Member of the Scientific Advisory Boardno datano datano data
Bruce Chabner
Member of the Scientific Advisory Boardno datano datano data
Ronald Evans
Member of the Scientific Advisory Boardno datano datano data
Joel Huff
Member of the Scientific Advisory Boardno datano datano data

4.6yrs

Average Tenure

60yo

Average Age

Experienced Board: EPZM's board of directors are considered experienced (4.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: EPZM insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 25.1%.


Top Shareholders

Company Information

Epizyme, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Epizyme, Inc.
  • Ticker: EPZM
  • Exchange: NasdaqGS
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.540b
  • Shares outstanding: 100.77m
  • Website: https://www.epizyme.com

Number of Employees


Location

  • Epizyme, Inc.
  • 400 Technology Square
  • 4th Floor
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EPZMNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMay 2013
EPEDB (Deutsche Boerse AG)YesCommon StockDEEURMay 2013
EPEBRSE (Berne Stock Exchange)YesCommon StockCHCHFMay 2013

Biography

Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors. It also develops tazemetostat in combination with R-CHOP that is in the Phase Ib/II clinical trials in elderly patients with DLBCL; and tazemetostat in combination with PD-L1 inhibitor, which is in the Phase Ib/II clinical trials for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer. In addition, the company is developing EZM8266, a G9a inhibitor that is in the Phase 1 study for the treatment of sickle cell disease; pinometostat, which is in the preclinical studies stage for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor that is in Phase II clinical trial for patients with solid tumors and NHL; and PRMT1 inhibitor, which is in the Phase 1 clinical trial. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Boehringer Ingelheim International GmbH; Roche Molecular Systems, Inc.; Lymphoma Study Association; and Eisai Co. Ltd. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/07 09:03
End of Day Share Price2020/04/06 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.